Opinion on Cardiovascular and Diabetes

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
Expert View
Expert View

Arena Pharmaceuticals: positive vote for Lorqess, but will commercial success follow?

Lorqess has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.

Published By Datamonitor
15 May 2012
CommentWire
CommentWire

Gilead Sciences: hoping to become the HCV market leader through Pharmasset takeover

Gilead Sciences' planned acquisition of Pharmasset will bring with it three promising mid- to late-stage hepatitis C drugs. If launched, these products would cement the company's position as the leading player in the infectious diseases market, an area within which it already has considerable expertise.

Published By Datamonitor
23 Nov 2011
Expert View
Expert View

Geron runs out of steam while others race ahead

Canada-based biotech Geron has abandoned its embryonic stem cell program for spinal cord injury citing funding scarcity. However, companies focused on the development of adult stem cells therapies for cardiovascular diseases, such as the US-based Athersys and Australia's Mesoblast, continue to fuel investors' confidence.

Published By Datamonitor
22 Nov 2011
Expert View
Expert View

Amylin's choice of ally for exenatide will be crucial in the wake of its split from Lilly

Having announced an end to its co-development and marketing deal with Eli Lilly covering exenatide antidiabetic products, Amylin is now looking for a bigger partner to drive sales of Byetta and the new once-weekly formulation Bydureon. Datamonitor believes that several major pharmaceutical players meet the criteria to become a suitable ally for the company in its ongoing development of exenatide.

Published By Datamonitor
11 Nov 2011
CommentWire
CommentWire

Lilly/Amylin: changing alliances shake up the Australian diabetes market

The future of Byetta in Australia is increasingly uncertain following the cessation of Amylin Pharmaceuticals' and Eli Lilly's decade-long alliance for diabetes treatment exenatide. Eli Lilly plans to hand back marketing rights for the drug by 2013, leaving Amylin to seek new partners outside the US. Unless a new partner is signed, the prospects of the drug are greatly diminished.

Published By Datamonitor
10 Nov 2011
Expert View
Expert View

Prolonged regulatory submission may harm GLP-1 agonists in Australia

The latest GLP-1 agonist to launch in Australia will not make much of an impression on the domestic diabetes market if it cannot achieve PBS listing before new pipeline candidates reach the island's shores. The current situation of prolonged regulatory negotiations in the country may soon become a major issue, keeping important drugs out of reach of patients.

Published By Datamonitor
05 Oct 2011
Expert View
Expert View

Dapagliflozin's "no" vote from FDA advisory committee spells trouble for new diabetes class

An FDA advisory panel has recommended against approving dapagliflozin, the most advanced candidate in the novel SGLT-2 inhibitor antidiabetic class. The FDA is likely to follow the committee's advice and require pre-approval trials to address unexpected safety concerns, particularly an excess of certain cancers seen during trials, and at least one case of probable drug-induced liver injury.

Published By Datamonitor
21 Jul 2011
Expert View
Expert View

Bydureon successful at FDA-mandated trial, but market uptake could prove tougher challenge

Pipeline antidiabetic drug Bydureon has overcome another obstacle to approval, with developers Amylin, Eli Lilly, and Alkermes announcing that supratherapeutic doses of the product do not cause a change in heart rhythm by affecting the QT interval. These results pave the way for the resubmission of Bydureon in the US later in 2011.

Published By Datamonitor
12 Jul 2011
CommentWire
CommentWire

Roche: Phase III results raise hopes for additional ophthalmic indication for Lucentis

Encouraging trial data presented at this year's American Diabetes Association meeting reveal that Roche's Lucentis significantly improves visual acuity among patients with diabetic macular edema. If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market. Nevertheless, off-label use of Avastin may temper sales.

Published By Datamonitor
01 Jul 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.